Vitreous humor in the pathologic scope: Insights from proteomic approaches. Issue 1 (19th January 2015)

• Record Type: Journal Article
• Authors: Monteiro, João P.; Santos, Fátima M.; Rocha, Ana S.; Castro‐de‐Sousa, João P.; Queiroz, João A.; Passarinha, Luis A.; Tomaz, Cândida T.; Dunn, Michael J.
• Is Part Of: Proteomics. Volume 9:Issue 1/2(2015)
• Page Start: 187
• Page End: 202
• Publication Date: 2015-01-19
• Subjects: Proteomics -- Periodicals; 572.605
• DOI: 10.1002/prca.201400133
• Languages: English
• ISSNs: 1862-8346

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>The vitreous humor (VH) is the largest component of the eye. It is a colorless, gelatinous, highly hydrated matrix that fills the posterior segment of the eye between the lens and retina in vertebrates. In VH, a diversity of proteins that can influence retinal physiology is present, including growth factors, hormones, proteins with transporter activity, and enzymes. More importantly, the protein composition of VH has been described as being altered in a number of disease states. Therefore, attempts aiming at establishing a map of VH proteins and detecting putative biomarkers for ocular illness or protein fluctuations with putative physiologic significance were conducted over the last two decades, using proteomic approaches. Proteomic strategies often involve gel‐based or LC techniques as sample fractioning approaches, subsequently coupled with MS procedures. This set of studies resulted in the proteomic characterization of a range of ocular disease samples, with particular incidence on diabetic retinopathy. However, practical therapeutic applications arising from these studies are scarce at the moment. A pertinent example of therapeutic targets arising from VH proteomics has emerged concerning vasoproliferative factors present in the vitreous, which should be involved in neovascularization and subsequent fibrovascular proliferation of the retina, in ocular disease context. Therefore, this review attempts to sum up the information acquired from the proteomic approaches to ocular disease conducted in VH samples, highlighting its clinical potential for disclosing ocular disease mechanisms and engendering pharmacological therapeutic treatments.</p> </abstract>